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ABSTRACT
Background: MYCN-amplification in high-grade Neuroblastoma (NB) tumors 
correlates with increased vascularization and therapy resistance. This study combines 
an anti-angiogenic approach with targeting NB metabolism for treatment.
Methods and Results: Metronomic cyclophosphamide (MCP) monotherapy 
significantly inhibited NB growth and prolonged host survival. Growth inhibition was 
more pronounced in MYCN-amplified xenografts. Immunohistochemical evaluation 
of this subtype showed significant decrease in blood vessel density and intratumoral 
hemorrhage accompanied by blood vessel maturation and perivascular fibrosis.  
Up-regulation of VEGFA was not sufficient to compensate for the effects of the 
MCP regimen. Reduced Bcl-2 expression and increased caspase-3 cleavage were 
evident. In contrast non MYCN-amplified tumors developed resistance, which was 
accompanied by Bcl-2-up-regulation. Combining MCP with a ketogenic diet and/or 
calorie-restriction significantly enhanced the anti-tumor effect. Calorie-restricted 
ketogenic diet in combination with MCP resulted in tumor regression in all cases.
Conclusions: Our data show efficacy of combining an anti-angiogenic 
cyclophosphamide dosing regimen with dietary intervention in a preclinical NB model. 
These findings might open a new front in NB treatment.
INTRODUCTION
Neuroblastoma (NB) represents the most common 
extracranial solid childhood cancer. Marked biological 
and clinical heterogeneity, pose strong challenges to 
optimizing therapeutic interventions for individual 
cases. Among others biological risk factors include 
MYCN status, tumor histology, cancer cell DNA content 
and defined segmental chromosomal aberrations [1–5]. 
In combination with historical clinical data, tumor biology 
allows clinicians to guide therapy by stratifying patients 
into internationally accepted risk groups [6, 7]. In low- and 
intermediate-risk groups, with overall survival rates above 
90%, recent studies have been focusing on reducing 
therapeutic toxicity. For patients in the high-risk group, 
however, improving treatment efficacy is still central with 
overall survival rates close to 50% despite multimodal 
therapy protocols [1]. 
With regard to cellular metabolism NBs share the 
characteristic reprogramming to high glucose uptake 
recently added to the hallmarks in cancer [8–10]. This 
preferential utilization of glucose via aerobic glycolysis 
even under sufficient oxygen to shunt pyruvate into 
oxidative phosphorylation (OXPHOS) pathway, is 
commonly described as Warburg effect [11, 12]. Whereas 
defects in single OXPHOS subunits can be a direct 
cause of the Warburg effect [13–15], other cancers show 
a general pattern of low OXPHOS activity [16–19]. 
In NB, both primary tumor tissue and xenografts 
display generalized low mitochondrial respiratory chain 
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activity [20, 21]. This metabolic feature might indicate a 
dependency on glucose not only for anabolic processes, 
but also for energy production. Based on this theory, we 
recently reported a preclinical study showing significant 
tumor growth inhibitory effects of dietary intervention in 
a NB xenograft model [21]. In that study we observed that 
a mild ketogenic diet (KD) and/or calorie restricted (CR) 
diet altered blood metabolic parameters (reduced glucose 
and increased beta-hydroxybutyrate levels) and induced 
significant growth inhibition of NB xenografts. Detailed 
evaluation of mitochondrial OXPHOS parameters showed 
no adaptive response in the NB tumors [21].
These growth inhibitory effects are in line with 
preclinical data on cancers of the central nervous system 
suggesting that CR-KD might constitute an adjuvant 
approach in cancer therapy [22–25]. Effects of CR 
and/or KD in diverse preclinical cancer models have 
recently been reviewed [26, 27]. Anecdotal case reports 
of cancer patients treated with CR-KD support a possible 
inhibitory effect on tumor growth, but comprehensive 
preclinical and clinical evaluation is lacking [28–30]. Pilot 
studies of KD in adult patients showed that it might be 
tolerated in patients with advanced cancers [31–33]. 
Because targeting cancer metabolism is 
complementary to current treatment strategies for NB, 
it could potentially open a new front against this tumor 
entity. The current study therefore aims to investigate 
the combination of KD and/or CR diet with a low-dose 
metronomic cyclophosphamide (MCP) chemotherapy 
regimen. MCP has been shown to effectively inhibit 
neoangiogenesis in xenograft models of different 
tumor entities [34–36] and is under clinical evaluation 
[37–40]. We hypothesize that concurrent targeting of 
tumor vascularization and cancer cell metabolism might 
constitute a cooperative therapeutic approach.
RESULTS
Inhibition of NB tumor growth by MCP in 
combination with dietary intervention 
In an effort to exploit a potential synergism of 
targeting vascular supply and cancer cell metabolism, 
we chose to combine dietary intervention with MCP. In 
the presented model, MCP induced significant growth 
inhibition (p < 0.001) of NB xenografts of both cell 
lines tested from day 9 onward and extended survival 
(p < 0.001) compared to the corresponding standard 
diet group without MCP (SD group w/o CTx; Figure 1). 
Intriguingly on the metronomic dosing protocol, 
growth inhibition of SK-N-BE(2) tumors was more 
pronounced versus that of tumors of the reportedly more 
chemotherapy sensitive SH-SY5Y cell line [41–43]. 
In addition to the chemotherapy-induced growth reduction, 
SH-SY5Y tumors showed a significant additional 
growth inhibition in all three dietary intervention groups 
(Figure 1A1). On day 36, tumor volume in the SD group 
was significantly greater compared to that of the calorie 
restricted-standard diet (CR-SD) group (p < 0.05), the KD 
group (p < 0.01) and the CR-KD group (p < 0.001). In the 
SK-N-BE(2) xenografts tumor growth was significantly 
inhibited in the restricted diet groups (Figure 1B1) 
CR-SD (p < 0.05) and CR-KD (p < 0.05). Based on the 
strong effect of MCP on SK-N-BE(2) tumor growth, 
observed absolute effect size of dietary intervention 
was limited. One mouse in the CR-SD group was found 
dead on day 22 form an undetermined cause. CR-KD 
in combination with MCP resulted in tumor regression 
all cases of SH-SY5Y and SK-N-BE(2). The fractional 
product of Webb [44] on the last day with available control 
tumor data showed synergism for KD and CR-KD for 
SH-SY5Y and CR-SD and KD for SK-N-BE(2). For the CR-
SD an additive effect and for the CR-KD in SK-N-BE(2) 
antagonism was observed (Supplementary Table S3). 
These results need to be interpreted with caution due to 
the small tumor size in the SK-N-BE(2) and the lack of 
dosing curves [44].
Effect of dietary intervention on blood glucose 
and ketone body levels
KD and/or CR caused consistent changes in blood 
glucose and ketone body levels in mice carrying the two 
different xenograft types. Data are given for day 36 or the 
last day of therapy (Figure 2A1–2A2 and 2B1–2B2). Blood 
glucose levels were significantly decreased in all four CR 
groups when compared to the SD group. In detail, blood 
glucose levels in SD group of SH-SY5Y were significantly 
higher when compared to CR-SD (p < 0.05) and CR-KD 
(p < 0.01). Ketone body levels were significantly elevated 
in the CR-KD group (p < 0.001) compared to the SD 
group, but not in the CR-SD. Glucose in the SK-N-BE(2) 
SD group was significantly higher compared to CR-SD 
(p < 0.01) and CR-KD (p < 0.01). Ketone body levels 
were significantly elevated in both the KD (p < 0.05) 
and CR-KD (p < 0.001) groups when compared to the 
SD group, but not in the CR-SD group. No significant 
changes in blood glucose were detected for neither of the 
KD groups. Detailed blood glucose and ketone body data 
for all time points is given in Supplementary Table S1. As 
published recently [45] the glucose ketone index (GKI), a 
ratio of blood glucose [mM] to blood ketone [mM] levels 
might help to monitor therapeutic efficacy in patients on 
ketogenic diets. Under the given food regimens, mice 
showed a GKI > 12 in the SD groups and GKI < 5 in the 
CR-KD diet group, on the last day of therapy. These ratios 
are consistent with other preclinical studies in mice [45]. 
Mean GKI is given in Figure 2A3 and 2B3 and shows 
a significant reduction in all dietary intervention groups 
(p < 0.001). GKI for all time points are given in 
Supplementary Table S2.
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Tumor and body weight
As tumor volume calculated by the described 
formula could be regarded as an approximation of 
tumor size, tumor weight was recorded after sacrificing 
mice. In line with the tumor volumes, tumor weight was 
significantly decreased in all groups on MCP (p < 0.001). 
Dietary intervention significantly enhanced suppression of 
tumor growth, evaluated as tumor weight, in all therapy 
groups (p < 0.05) except for the KD group of SK-N-
BE(2) (Figure 2A3 and 2B3). No significant change in the 
tumor volume (mm^3) to weight (mg) ratio was observed 
(p > 0.05) (Supplementary Figure S1). Treatment with MCP 
did not significantly change mouse weight on the last day 
of therapy in mice on SD or KD (p > 0.05) (Supplementary 
Figure S2). The combination of MCP with CR caused a 
significant change in mouse weight for all four therapy 
groups when compared to the corresponding SD group 
(p < 0.05). For one mouse in the CR-KD group therapy 
was discontinued due to progressive weight loss on 
day 29. Detailed body weight data for all time points is 
given in Supplementary Table S1.
Effect of MCP and dietary intervention on 
proliferation indices in NB xenografts
To further elucidate the tumor growth inhibitory 
effect of the combination of MCP and/or dietary 
intervention, we evaluated proliferative activity by 
scoring the markers Ki67 and PHH3. The staining patterns 
revealed similar effects of MCP and dietary intervention 
on proliferation indices in xenografts of the two cell lines. 
Ki67 levels did not differ significantly when comparing the 
non-restricted and CR groups receiving MCP treatment to 
the corresponding SD group w/o CTx (p > 0.05; Figure 3A1 
and 3B1). The expression of PHH3, a marker for M-phase 
of the cell cycle, was significantly lower in the CR 
SH-SY5Y xenografts (p < 0.01, Figure 3A2) as well as 
in CR SK-N-BE(2) xenografts (p < 0.001, Figure 3B2). 
Proliferation indices for each individual subgroup SD/
Figure 1: Dietary intervention enhances the growth inhibitory effect of MCP on NB xenografts. After establishing tumors, 
mice were randomized to therapy and control groups as indicated. For xenografts of both cell lines the MCP regimen significantly inhibited 
tumor growth compared to the SD group w/o CTx (p < 0.001). (A1) SH-SY5Y and (B1) SK-N-BE(2) tumor growth curves. Data points 
represent mean values ± SEM of the corresponding therapy group (n = 8–12). (A2) and (B2) show Kaplan–Meier survival curves for mice 
with SH-SY5Y and SK-N-BE(2) xenografts respectively. Survival was significantly prolonged in all therapy groups when compared to 
the SD group w/o CTx (p < 0.001). The effect of dietary intervention on tumor growth was evaluated by comparing diet groups to the 
corresponding SD on MCP. Significance levels are given for each dietary intervention group compared to SD on MCP and are stacked from 
the group with lowest to highest tumor volume. Statistics: ANOVA (p < 0.05) followed by two-tailed Dunnett´s test correcting for multiple 
comparisons; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. Differences in survival were determined in a univariate analysis with the log-rank test. 
Death is coded: tumor volume above 3000 mm3, tumor ulceration or impaired health condition. Abbrev.: SD, standard diet; CR, calorie 
restriction; KD, ketogenic diet; w/o CTx, without chemotherapy; MCP, metronomic cyclophosphamide.
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KD and CR-SD/CR-KD are given in Supplementary 
Figure S3. Together these results indicate that reduced 
cell division might play a role in the growth inhibitory 
effect of CR, but does not explain the pronounced effect 
of MCP in the more chemotherapy-resistant (SK-N-BE(2)) 
xenografts. 
In vitro 4-hydroperoxycyclophosphamide  
(4-HC) sensitivity
Because the in vivo results showed MCP to be more 
active against xenografts of the reportedly chemotherapy-
resistant cell line SK-N-BE(2), we compared the in vitro 
CP-sensitivity of SH-SY5Y and SK-N-BE(2) to confirm 
the data reported in the literature [41–43]. We therefore 
titrated 4-HC concentration (active metabolite of CP) 
to a dose-range, in which both cell lines showed either 
complete cell death (10 nM) or no difference in survival 
(0.313 nM) under the conditions tested. At all intermediate 
doses SH-SY5Y showed significantly higher sensitivity 
to 4-HC (Supplementary Figure S6). From these data we 
hypothesized that, rather than a direct cytotoxic effect, 
an indirect effect on xenograft growth may be rendering 
SK-N-BE(2) tumors more susceptible to MCP. To our 
knowledge this has not been shown in literature before.
Macroscopic observation of intratumoral 
hemorrhage
Macroscopic inspection and evaluation of photo 
documentation showed a tendency to stronger intratumoral 
hemorrhage in the SK-N-BE(2) xenografts compared to 
SH-SY5Y xenografts (Figure 4A1 and 4B1). We therefore 
quantified macroscopic hemorrhage at day 36 or the last 
day of therapy (Figure 4A2 and 4B2). In the SK-N-BE(2) 
group on SD w/o CTx, 100% (8/8) of tumors showed 
pronounced macroscopic hemorrhage. On therapy with 
MCP this was reduced to 20% (5/25), which approximates 
the level of hemorrhage observed in SH-SY5Y xenografts 
(22%, 2/9) without MCP. In the SH-SY5Y xenografts, 
MCP reduced macroscopic hemorrhage to a level of 6% 
(2/35). Intratumoral hemorrhage did not vary between 
dietary subgroups and is given in Supplementary 
Figure S4.
Figure 2: Blood glucose reduction and induction of ketosis goes with reduced tumor weight in mice under MCP. 
(2A) SH-SY5Y groups and (2B) SK-N-BE(2) groups. (A1) and (B1) CR significantly reduced blood glucose levels in mice with both 
xenograft types. (A2) and (B2) Ketone body levels (beta-hydroxybutyrate) were consistently elevated in the CR-KD groups and the KD 
group of SK-N-BE(2). The trend in the KD group of SH-SY5Y did not reach statistical significance. (A3) and (B3) Mean Glucose Ketone 
Index over the treatment period was significantly reduced in all dietary intervention groups (p < 0.001). (A4) and (B4) Tumor weight was 
significantly reduced in all groups on MCP when compared to the SD group w/o CTx (p < 0.001; data not shown) and dietary intervention 
groups as given. The results are consistent with the tumor volumes calculated in Figure 1A and 1B. Data are shown for day 36 or the last 
day of therapy. Mean values ± SEM of the corresponding therapy group are given (n = 8–12). Statistics: ANOVA (p < 0.05) followed by 
two-tailed Dunnett´s test correcting for multiple comparisons; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. Abbrev.: SD, standard diet; CR, calorie 
restriction; KD, ketogenic diet; w/o CTx, without chemotherapy; MCP, metronomic cyclophosphamide.
Oncotarget17064www.impactjournals.com/oncotarget
Effect of MCP on microscopic tumor 
vascularization, hemorrhage and vessel 
maturation
To further substantiate the results from macroscopic 
inspection, tumor vascularization and intratumoral 
hemorrhage were studied on tumor sections stained 
with Hematoxylin/Eosin (Figure 5A1 and 5B1). In line 
with the macroscopic observations, vascularization and 
hemorrhage were significantly higher in the SK-N-BE(2) 
xenografts compared to SH-SY5Y tumors. Upon MCP 
treatment, hemorrhage in both xenograft types was 
significantly reduced (p < 0.01). Along with the significant 
reduction of vascularization in the SK-N-BE(2) xenografts 
(p < 0.05), maturation of blood vessels was observed in 
xenografts of this cell type (Figure 6B). Angiogenesis 
scoring across all subgroups is given in Supplementary 
Figure S5. The change in vessel structure seemed even 
more fundamental than the reduction of vessel number. 
Increased nuclear accumulation of HIF1A was evident in 
the SK-N-BE(2) xenografts exposed to MCP. This was 
accompanied by central regions of cell death (Figure 5C) 
and VEGF up-regulation (Figure 5D). Increased VEGFA 
could not compensate for the anti-angiogenic effect of 
the MCP therapy.  It can be speculated that the marked 
increase in diffusion distance (as can be seen in Figure 6B1 
and 6B2, right) likely contributes to the increasing tissue 
hypoxia and cell death as depicted in Figure 5C.
Endothelial cell marker msCD-31 and Van Gieson 
staining were used to further characterize the nature of 
the prominent hemorrhage in SK-N-BE(2) xenografts. 
msCD-31 staining of SK-N-BE(2) tumors showed a poorly 
defined vascular pattern largely lacking both mature 
vessel structure and a basal membrane. Blood vessels of 
all diameters were strongly invaded by NB tumor cells, 
resulting in erythrocyte leakage into the tumor (Figure 6B1 
and 6B2, left). Only rare blood vessels in the periphery 
of SK-N-BE(2) xenografts showed an intact vessel 
structure with prominent basal lamina, as was consistently 
observed in the SH-SY5Y xenografts (Figure 6A1 and 
6A2 left). Under MCP treatment, however, in addition to 
a reduction of overall blood vessel density, a pronounced 
maturation of blood vessels was evident in SK-N-
BE(2) tumors (Figure 6B1 and 6B2, right). No tumor 
cell invasion into vascular structures was observed in 
SK-N-BE(2) xenografts exposed to MCP. This change of 
pattern was not observed in SH-SY5Y xenografts, where 
both treatment groups showed relatively-well developed 
vascular patterns (Figure 6A1 and 6A2). Compared to SD 
tumors w/o CTx MCP treated tumors showed a tendency 
towards decreased cellularity and reduced nucleus/cytosol 
ratio in both SH-SY5Y and SK-N-BE(2) xenografts.
Figure 3: Reduced proliferation contributes to the growth inhibitory effect of CR but not MCP. (3A) SH-SY5Y groups 
and (3B) SK-N-BE(2) groups. IHC evaluation of proliferation markers on day 36 or the last day of therapy. (A1) and (B1) The fraction 
of Ki67 positive stained cells was not significantly altered by MCP or diet when compared to SD w/o CTx. (A2) and (B2) In xenografts 
of both cell lines, PHH3 positive cells per high power field were significantly lower in the CR groups. (A3) and (B3) Exemplary tumor 
sections stained for PHH3 from mice on SD w/o CTx (left) and CR-KD (right) are shown. Scale bar = 50 µm. Mean values ± SEM of the 
therapy group are given (n ≥ 8). Statistics: ANOVA (p < 0.05) followed by two-tailed Dunnett´s test correcting for multiple comparisons; 
**p ≤ 0.01; ***p ≤ 0.001. Abbrev.: Ad libitum: SD/KD; restricted: CR-SD/CR-KD. SD, standard diet; CR, calorie restriction; KD, ketogenic 
diet; w/o CTx, without chemotherapy. Proliferation indices for individual dietary subgroups are given in Supplementary Figure S3.
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Diametrically opposed regulation of Bcl-2  
protein levels in SH-SY5Y and SK-N-BE(2) 
tumors under MCP
For both cell lines used in our study, Bcl-2 
expression was described previously [46] and was 
confirmed by IHC-staining in our study. Under continuous 
MCP treatment, SH-SY5Y xenografts of mice on SD 
showed a progressive increase in tumor volumes starting 
around treatment day 16. Along with this resistance, 
significantly higher Bcl-2 (p < 0.01; Figure 7A) 
expression was evident in xenografts exposed to MCP 
treatment compared to SD w/o CTx. This is in line with the 
literature for NB tumors, which suggest Bcl-2 upregulation 
as a mechanism of chemotherapy resistance under 
standard treatment [47, 48]. Consistent with the tumor cell 
characteristics [48] (chemotherapy resistant and MYCN 
amplified) the SK-N-BE(2) cell line showed increased 
basal Bcl-2 protein expression levels in the untreated 
group when compared to SH-SY5Y. On MCP treatment, 
however, Bcl-2 protein levels were significantly reduced 
in the SK-N-BE(2) xenografts (p < 0.001; Figure 7B). 
Whereas Bcl-2 staining was more preserved in 
vascularized areas, it was particularly low with increased 
distance to blood vessels (Figure 7B2, right). Western 
blot analysis (Figure 7C) supports the results from IHC. 
Whereas SH-SY5Y tumors exhibited slightly increased 
Bcl-2 levels upon prolonged MCP treatment, SK-N-BE(2) 
tumors showed decreased levels. Concomitant with the 
decrease in Bcl-2 levels, an increase in cleaved caspase 3 
was observed in MCP-treated SK-N-BE(2) xenografts. 
These results support the higher sensitivity of SK-N-BE(2) 
tumors to MCP as observed by tumor volume.
DISCUSSION
The present study combines two alternative 
therapeutic approaches to reduce NB tumor growth in a 
preclinical model. In this setting, administering an anti-
angiogenic MCP regimen with dietary intervention was 
able to significantly inhibit growth of NB xenografts of 
distinct genetic background and chemotherapy sensitivity.
In line with our previous work that focused 
exclusively on the effect of dietary intervention [21], KD 
and/or CR reduced glucose availability and increased 
blood ketone body levels in mice. Significant reductions of 
Figure 4: Predominant intratumoral hemorrhage in MYCN-amplified tumors is reduced upon MCP treatment. 
(4A) SH-SY5Y and (4B) SK-N-BE(2) tumors. Images of xenograft sites, as well as tumors after explantation are shown. Pronounced 
macroscopic hemorrhage in the SK-N-BE(2) SD group w/o CTx compared to all other therapy groups of both cell lines was evident. 
(A1) and (B1) Specimens from SD w/o CTx compared to SD on MCP are shown. (A2) and (B2) Relative quantification of macroscopically 
visible hemorrhagic tumors w/o CTx (SH-SY5Y n = 9, SK-N-BE(2) n = 8) and groups on MCP (SH-SY5Y n = 35, SK-N-BE(2) n = 25). 
Intratumoral hemorrhage did not vary between dietary subgroups and is given in Supplementary Figure S4. Abbrev.: SD, standard diet; 
w/o CTx, without chemotherapy; MCP, metronomic cyclophosphamide.
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tumor growth, in addition to MCP treatment, was evident in 
all dietary intervention groups except for the SK-N-BE(2) 
xenograft group on KD. Although dietary effects in 
the SK-N-BE(2) subgroup should be interpreted with 
caution due to the small absolute tumor size, results of 
different subgroups align with our previous work [21]. 
This supports the metabolic dependency of NBs and their 
limited capacity to adapt to the change in nutrient supply. 
In contrast to other studies on the effect of KD and/
or CR on tumor growth [21, 49–51], we not only observed 
growth inhibition, but also regression of tumor volume. 
Intriguingly, the combination of MCP and CR-KD 
induced a significant reduction of tumor size and complete 
growth arrest of NB xenografts of both cell lines tested. 
This highlights the importance of combining dietary 
intervention with other therapeutic approaches as it 
might sensitize tumors to the cytotoxic effects of these 
therapeutics. In line with our data, enhancement of anti-
tumor effect has been described in additional preclinical 
studies [52–54].
For NB, increased vascularization has been proposed 
to correlate with high-risk tumor stage and poor clinical 
outcome [55–57]. Targeting neovascularization has 
therefore been put forward as a therapeutic option [58–61]. 
Furthermore, a direct link between MYCN amplification 
and enhanced angiogenesis has been described [55, 62, 63]. 
In accord we observed increased angiogenesis and a 
highly invasive growth pattern in xenografts of the 
MYCN-amplified cell line. Upon MCP treatment, this 
phenotype changed to a mature vessel pattern with strong 
perivascular collagen deposition and without vascular 
invasion of tumor cells. To our knowledge this effect has 
not been described before. The change in vessel structure 
presumably resulted in undersupplied tumors due to 
the increased diffusion distance. This interpretation is 
supported by the increase in hypoxic areas with central 
Figure 5: Microscopic evaluation supports an anti-angiogenic effect of MCP and vessel maturation in NB xenografts. 
(5A1) SH-SY5Y and (5B1) SK-N-BE(2). Hematoxylin/Eosin staining of NB sections on day 36 or the last day of therapy was scored for 
angiogenesis and hemorrhage on a scale from 0-3. In the SK-N-BE(2) xenografts, blood vessel morphology changed to a more mature 
pattern as described in detail in Figure 6B1 and 6B2. (C) IHC staining for HIF1A of a SK-N-BE(2) xenograft section from the SD group 
w/o CTx (upper) and SD on MCP (lower). Blood vessel (arrow) rarefication and maturation caused a hypoxic pattern in SK-N-BE(2) 
xenografts with increased nuclear HIF1A accumulation and areas of marked cell death in the center of hypoxic areas (asterisk). (D) This 
correlated to VEGFA up regulation in SK-N-BE(2) xenografts exposed to MCP, as depicted by immunoblotting. Scale bars = 100 µm 
(overview) and 50 µm (detail). Mean values ± SEM of the therapy group are given (n ≥ 8). Statistics: unpaired t test (p < 0.05); *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001. Angiogenesis scoring across all subgroups is given in Supplementary Figure S5. Densitometry for VEGFA levels 
is given in Supplementary Figure S8A. Abbrev.: SD, standard diet; w/o CTx, without chemotherapy; MCP, metronomic cyclophosphamide. 
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cell death as seen on HIF1A staining. Direct evidence for 
nutrient deprivation, however, is pending. 
Whereas the SH-SY5Y xenografts in the SD group 
developed resistance to the MCP regimen that was 
accompanied by up-regulation of Bcl-2 levels, in the 
reportedly more chemotherapy-resistant SK-N-BE(2) 
xenografts [41–43], sensitivity was retained. The increased 
in vitro chemotherapy resistance of the SK-N-BE(2) 
cells supports an anti-tumor mechanism of MCP that is 
not linked to a direct cytotoxic effect. Previous reports 
showed that in vitro hypoxia can trigger an autocrine loop 
via increased VEGF expression to induce Bcl-2 mediated 
chemotherapy resistance in SK-N-BE(2) cells [64, 65]. 
Although our model supports findings of increased 
VEGFA expression in response to hypoxia, this loop was 
not sufficient to induce Bcl-2-mediated tumor cell survival 
in the in vivo setting. 
This finding might highlight the importance of a 
concomitant decrease in nutrient supply that accompanies 
the state of low vascularization in tumors which is often 
not prioritized in in vitro studies [64, 65]. Supporting 
published work on an anti-angiogenic effect of KD [66], 
we observed the strongest reduction of angiogenesis in the 
combination of KD with MCP. Whereas both publications 
report a rarefication of blood vessels and hemorrhage, 
the fibrous depositions and vessel maturation are only 
described in our model.
Figure 6: Evaluation of blood vessels by IHC for msCD-31 endothelial cell marker (A1, B1) and Van Gieson staining 
of collagen fibers (A2, B2). Images show exemplary sections of (6A) SH-SY5Y and (6B) SK-N-BE(2) xenografts at day 36 or the last 
day of therapy. The left upper (overview) and lower (detail) images are taken from tumors w/o CTx, the right upper and lower images are 
from tumors exposed to MCP. (A1) and (B1) show IHC staining for the endothelial marker msCD-31. Under both conditions SH-SY5Y 
xenografts show well-formed blood vessels, as can be appreciated best in the detail section (A1, lower). In comparison SK-N-BE(2) 
xenografts show marked difference in blood vessel morphology between the w/o CTx group and the MCP group (B1). (A2) and (B2) 
Van Gieson staining identified the strong perivascular connective tissue in the SK-N-BE(2) group on MCP as collagen deposition (red). 
Blood vessels are marked by arrows, Scale bars = 100 µm (overview) and 50 µm (detail). Abbrev.: SD, standard diet; w/o CTx, without 
chemotherapy; MCP, metronomic cyclophosphamide.
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Although we are aware of the limitations of 
an ectopic xenograft model and potential effects of 
additional molecular differences between the cell lines, 
the pronounced effect on tumor growth inhibition and 
blood vessel maturation could help to further clarify 
mechanisms in this molecular subgroup of NBs [62]. 
It can be hypothesized, that along with the increased 
vascularization, also a stronger dependency on vascular 
supply is present for promoting tumor growth. Together 
with targeting cell metabolism this might constitute an 
Achilles heel worth aiming for to improve treatment for 
therapy-refractory NB.
Figure 7: SH-SY5Y (A) and SK-N-BE(2) (B) cell lines show divergent regulation of Bcl-2 levels under MCP. (A1) and 
(B1) Bcl-2 levels on IHC staining were scored on day 36 or the last day of therapy. In the untreated state, SH-SY5Y xenografts showed 
significantly lower Bcl-2 levels when compared to SK-N-BE(2) xenografts (p < 0.001). On MCP treatment, the two cell lines showed an 
opposing response. (A2) and (B2) Exemplary Bcl-2 IHC-stained sections w/o CTx (left) and on MCP (right). (C) On western blot analysis, 
along with the reduction in Bcl-2 levels, increased cleaved caspase 3 protein was detected in the SK-N-BE(2) xenografts exposed to MCP. 
Densitometry for western blots is given in Supplementary Figure S8B.Scale bar = 100 µm; Mean values ± SEM of the therapy group are 
given (n ≥ 8). Statistics: Stundent´s t test (p < 0.05); **p ≤ 0.01, ***p ≤ 0.001. Abbrev.: SD, standard diet; w/o CTx, without chemotherapy; 
MCP, metronomic cyclophosphamide.
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MATERIALS AND METHODS
Cell lines
Neuroblastoma xenografts were established with 
the cell lines (ATCC, Manassas, VA, USA) SH-SY5Y 
(CRL-2266) and SK-N-BE(2) (CRL-2271). SH-SY5Y 
is a TP53 wild type, non-MYCN-amplified cell line with 
no chromosome 1p loss of heterozygosity and is sensitive 
to chemotherapy. The SK-N-BE(2) cell line is highly 
resistant to a wide range of chemotherapeutic agents and 
is characterized by MYCN-amplification, TP53 mutation 
(p.C135F) and chromosome 1p loss of heterozygosity [41]. 
Cells were cultured in standard conditions as described 
earlier [21]. MYCN expression on protein level was 
confirmed on western blot and is given in Supplementary 
Figure S7.
Animal models and sample preparation
All in vivo experiments were performed in 
accordance with protocols approved for this study by the 
Salzburg Animal Care and Use Committee (Nr.: 20901-
TVG/44/7-2011). This protocol specifically addressed 
weight loss observed in response to dietary intervention. 
Animals were maintained under specific pathogen-free 
conditions and care conformed to the Austrian Act on 
Animal Experimentation. Xenograft growth was induced 
on the right flanks of 5-to 6-week-old female CD-1 
nude mice (Charles River, Wilmington, MA, USA) by 
subcutaneous injection of a 200 µl suspension of NB 
cells (2.7 × 107) in serum-free medium and matrigel 
(BD Bioscience, Franklin Lakes, NJ, USA). After 
reaching a tumor size of 350 mm3, an oral metronomic 
cyclophosphamide treatment was started and mice were 
randomized to four dietary therapy groups (SD, CR-
SD, KD and CR-KD; n = 10–12). One control group on 
standard diet without chemotherapy was included for both 
cell lines (SD w/o CTx; n = 8–9). 
Two times per week, tumor volumes were measured 
using a caliper and calculated according to the formula 
width x height x length / 2. Body weight was recorded and 
blood glucose and ketone body (beta-hydroxybutyrate) 
levels were monitored using enzyme based methods twice 
weekly (Precision Xceed, Abbott Laboratories, North 
Chicago, IL). In the ad libitum-fed groups, measurements 
were performed after a two-hour fasting period or before 
feeding in the calorie restricted groups. Animals in CR 
groups were single-housed to control food intake. Ad 
libitum-fed mice were group housed. Mice were sacrificed 
at day 36 or when termination criteria were met (health 
status, tumor ulceration or volume of 3000 mm3). Images 
of the xenografts were recorded at the start of therapy, 
and before and after removal of the tumor. Cancer tissue 
was snap frozen in liquid nitrogen. One 0.5 cm tumor 
slice each was formalin-fixed and paraffin embedded for 
histological analysis.
Food composition and energy content
Mice were fed according to four different regimens: 
standard diet ad libitum (SD), calorie restricted standard 
diet (CR-SD), long-chain fatty acid-based ketogenic diet 
ad libitum (KD) and calorie-restricted ketogenic diet 
(CR-KD). Detailed food composition and feeding 
protocols to evaluate the dietary intervention on NB-tumor 
growth were published previously [21] and are given in the 
Supplementary Data (Table S4). In brief, the metabolizable 
energy contents were: SD (kcal: fat 9%, protein 33% and 
carbohydrates 58%) and mild KD (kcal: fat 78%, protein 
14% and carbohydrates 8%) (No. V1535-000 and No. 
S9139-E02D; Sniff Spezialdiäten GmbH, Soest, D). Diets 
were fortified with vitamins and mineral supplements. For 
the CR groups, food intake was restricted to 2/3 of the 
respective ad libitum intake, which aligns with clinical 
protocols for therapy-resistant epilepsy [67–69].
Metronomic cyclophosphamide (MCP) schedule
CP (Sigma, St Louis, MO, USA) was administered 
orally through the drinking water as described previously 
[70]. In order to achieve the described oral dose of 40 mg/kg 
CP per day, final CP concentration in drinking water was 
0.266 mg/ml [70]. Analogous MCP regimens were applied 
to target neoangiogenesis in xenograft models of other 
tumor entities [34–36] and have low toxicities [70, 71]. 
Average water/CP intake per mouse was equal between 
different diet groups.
In vitro CP sensitivity
In vitro CP sensitivity of both cell lines was 
evaluated by utilizing 4-hydroperoxycyclophosphamide 
(4-HC, Niomech, Bielefeld, D), an active metabolite of CP. 
Cells were seeded in 96 well plates (25 000/well). After 
resting for 48 hours, standard medium was replaced by 100 
µl medium containing 4-HC (0.157 – 10 nM). 4-HC was 
freshly dissolved in DMSO (Sigma), and control medium 
contained the maximum DMSO concentration (0.01%). 
After three hours of drug exposure, the medium was 
replaced by 100 µl standard medium for 24 hours to allow 
the cytotoxicity to fully develop. 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay 
was performed following the manufacturer’s instructions 
(Life Technologies, Carlsbad, CA, USA). Absorbance 
was read at 570 nm with an EnSpire Multimode Plate 
Reader (PerkinElmer, Waltham, MA, USA). Results were 
normalized to background and are given as metabolic 
activity relative to control (100%). The average of two 
independent experiments with 6 replicates each is shown.
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(Immuno-)histochemical staining and analysis
Histological staining was performed using 
5-µm deparaffinized tumor sections of NB xenografts. 
Hematoxylin/eosin and Van Gieson staining as well as 
immunohistochemistry (IHC) stainings (Bcl-2 (B-cell 
lymphoma 2), PHH3 (phospho-histone H3), Ki67) were 
carried out within the routine diagnostic setting at the 
local pathology department following standard protocols. 
Antibodies were used at the following dilutions: 1:100 
for anti-Bcl-2 (Dako, Glostrup, Denmark), 1:200 for 
anti-PHH3 (Cellmarque, Rocklin, CA, USA) and 1:500 for 
anti-Ki67 (Dako). Angiogenesis, intratumoral hemorrhage 
and Bcl-2 staining were scored on a scale of 0 (none) to 3 
(strong). Proliferation indices were scored by evaluating 
the proportion of positively stained nuclei scoring at 
least 500 cells per slide (Ki67) or counting the number 
of positively stained tumor nuclei per high-power field 
(PHH3/HPF). For adequately sized tumors, at least five 
representative regions were scored; magnification was 
400-fold. When the tumor size was too small, stained 
nuclei/total tumor cells were counted and converted to a 
HPF equivalent. Anti-msCD31 (Abcam, Cambridge, UK) 
and anti-HIF1A (hypoxia-inducible factor 1-alpha, Novus, 
Littleton, USA) stainings were carried out at a dilution 
of 1:50 and 1:100, respectively, following protocols for 
IHC-staining described earlier [19, 72]. For detection 
EnVision kit reagents (Dako) were used following the 
manufacturer’s instructions. Analysis of histological 
staining was performed by two blinded investigators, and 
the mean of both scores was calculated. 
Western blot analysis
Whole-cell lysates for western blot analysis were 
prepared using standard radioimmunoprecipitation 
assay buffer. In brief, 30 µg protein were separated on 
10% acrylamide/bis-acrylamide gels before transfer 
to polyvinylidene difluoride membranes (Bio-Rad, 
Hercules, CA, USA) using CAPS buffer (10 mM 
3-[cyclohexylamino]-1-propane sulfonic acid, pH 11; 10% 
methanol). The following primary antibodies were diluted 
in 5% w/v BSA (Sigma) in TBS-T: 1:1000 anti-Bcl-2 
(Dako), 1:1000 anti-cleaved caspase 3 (Cell Signaling 
Technologies, Danvers, MA, USA), 1:30 000 anti-tubulin 
(Promega, Madison, WI, USA), 1:1000 anti-VEGFA 
(vascular endothelial growth factor, Abcam) and 1:1000 
anti-NMYC (Abcam). Horseradish peroxidase-labeled 
secondary antibodies were used (Dako) and detection 
was carried out with Lumi-Light POD-substrate (Roche, 
Basel, Switzerland). Quantification of band intensities was 
performed using Image Lab Software 5.2.1 (Bio-Rad) and 
adapted to the corresponding loading control.
Statistics
Statistical analysis was performed by Student´s t test 
(two groups; p < 0.05) and one-way ANOVA (more than 
two groups; p < 0.05). To adapt for multiple comparisons 
two-tailed Dunnett´s posttest was used. In these cases 
multiplicity adjusted p-value is given. If not mentioned 
otherwise, results are given as mean ± SEM. The analyses 
were performed using Prism 6 (GraphPad Software, La Jolla, 
CA, USA) and SPSS 21 (IBM, Armonk, NY, USA). The 
fractional product of Webb was used to determine whether 
the observed effects show synergistic or additive nature. 
The method uses the formula: i
1,2 
= i
1
*i
2
; where i
1,2
 is the 
inhibitory fraction of the combination of two interventions 
i
1
 (cyclophosphamide) and i
2
 (diet). When the predicted 
response exceeds the measured response, synergism is 
claimed (Ratio calculated/hypothetical < 1) [44].
Abbreviations
NB, neuroblastoma; SD, standard diet; CR, calorie 
restriction; KD, ketogenic diet; w/o CTx, without 
chemotherapy; MCP, metronomic cyclophosphamide.
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